Abstract
Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have